The August 2026 edition of the 1Cell.Ai Newsletter explores a critical shift in precision oncology: moving beyond diagnosis by morphology and beyond genomics alone to understand the complete biology of cancer. This issue examines why a single biopsy, mutation profile, or IHC result may not be enough particularly in complex and heterogeneous tumors and how multimodal approaches are helping clinicians uncover answers conventional diagnostics can miss.
A key highlight is the OncoIndx® Multimodal case in sarcoma, where an inconclusive diagnosis of metastatic spindle cell neoplasm was transformed into a definitive Low Grade Fibromyxoid Sarcoma diagnosis. By integrating DNA + RNA sequencing, the platform identified a FUS::CREB3L2 fusion, confirmed by 11.5-fold MUC4 RNA overexpression, while simultaneously ruling out more than 11 competing sarcoma diagnoses. The case demonstrates how integrated molecular profiling can turn diagnostic uncertainty into actionable clinical clarity.
The newsletter also looks at where precision oncology is heading next from the growing recognition that genomics alone may have limitations, to the rise of functional precision medicine, longitudinal ctDNA monitoring, RNA-based diagnostics, AI-assisted decision-making, and multimodal profiling. It also features 1Cell.Ai’s participation at the 4th Leading Cancer Care Summit 2026 in Bangkok and highlights major oncology developments from NCI, ASCO Breakthrough 2026, and global health policy. For oncologists interested in how the next generation of precision oncology could change diagnosis, treatment selection, and patient management, this is an issue worth reading in full.